Core Insights - EyePoint Pharmaceuticals reported a revenue of $11.59 million for the quarter ended December 2024, reflecting a decline of 17.4% year-over-year and a significant miss of 21.04% against the Zacks Consensus Estimate of $14.68 million [1] - The company's earnings per share (EPS) was -$0.64, worsening from -$0.33 in the same quarter last year, with a surprise of -56.10% compared to the consensus estimate of -$0.41 [1] Revenue Breakdown - Royalty income was reported at $0.22 million, falling short of the estimated $0.35 million by three analysts, representing a year-over-year decline of 10.4% [4] - Revenue from license and collaboration agreements was $10.59 million, below the average estimate of $13.86 million, marking an 18.7% decrease year-over-year [4] - Product sales, net, reached $0.77 million, slightly exceeding the two-analyst average estimate of $0.70 million, showing a year-over-year increase of 3.3% [4] Stock Performance - Over the past month, shares of EyePoint Pharmaceuticals have decreased by 20.2%, contrasting with a decline of 4.1% in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Summary of EyePoint Pharmaceuticals (EYPT) Conference Call Company Overview - **Company**: EyePoint Pharmaceuticals - **Focus**: Leader in sustained release drug delivery for retinal diseases, specifically targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD) with its lead product DuraView, which contains the drug virolinib [5][6] Key Points from the Conference Call Industry Context - **Market Size**: The global market for diabetic macular edema (DME) is projected to approach $4 billion within five years, with an estimated 50 million diabetics in the U.S. by then, and one in four expected to develop DME [14][15] - **Unmet Need**: There is a significant unmet need for durable treatments in DME, as many patients do not adhere to treatment schedules, leading to severe visual loss [15] Product Development and Trials - **DuraView**: - A sustained release drug delivery system that provides continuous dosing for at least six months [8][12] - Currently undergoing two global Phase III non-inferiority pivotal trials in wet AMD, with enrollment expected to complete in the second half of the year [6][34] - **VIRONA Trial**: - A Phase II clinical trial for DME showing promising results, including a best corrected visual acuity (BCVA) improvement of 7.1 letters and a significant central subfield thickness (CST) improvement of 76 microns [20][21] - 73% of patients in the DuraView 2.7 mg arm were supplement-free at six months compared to 50% in the control group [26][21] Safety and Efficacy - **Safety Profile**: No ocular or systemic serious adverse events (SAEs) reported in the trial, indicating a favorable safety profile for DuraView [21][30] - **Efficacy**: - DuraView demonstrated immediate bioavailability and sustained delivery, with significant improvements in both vision and anatomy observed as early as week four [31][32] - The trial's unique supplemental criteria contributed to the majority of supplements, but the overall results remained strong [20][19] Future Plans - **Phase III Protocol**: - Planning to discuss the proposed Phase III clinical protocol with regulatory agencies, aiming for a non-inferiority design [32][33] - Anticipating initiation of the pivotal program by the end of 2025, leveraging experience from ongoing trials to enhance efficiency [33][39] - **Manufacturing Facility**: A new 41,000 square foot manufacturing facility opened in October 2024, expected to supply DuraView for the DME Phase III trial and future commercial needs [37][38] Market Positioning - **Competitive Advantage**: DuraView's sustained release mechanism and favorable safety profile position it well against competitors, especially in a market where patients often struggle with treatment adherence [63][87] - **Regulatory Outlook**: Optimism regarding the potential for a single Phase III trial based on recent regulatory precedents [73] Analyst Questions and Responses - **Outlier Impact**: Discussion on how a single outlier patient affected the results, with confidence that larger trials will mitigate such effects [46][48] - **Market Acceptance**: The potential for DuraView to be widely accepted in the market due to its dosing schedule and safety profile, regardless of competing products [63][62] Conclusion EyePoint Pharmaceuticals is advancing its DuraView product through promising clinical trials, addressing a significant unmet need in the DME market. The company is well-positioned for future growth with a strong safety profile, innovative drug delivery technology, and a strategic plan for regulatory engagement and market entry.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 480 Pleasant Street Watertown, MA (Address of principal executive offices) 26-2774444 (I.R.S. Employer Identification No.) 02472 (Zip Code) ☐ TRANSITION REPORT PURS ...

Financial Data and Key Metrics Changes - Total net revenue for Q2 2022 was $11.6 million, an increase from $9 million in Q2 2021, representing a 30% growth [38] - Net product revenue for Q2 2022 was $11.3 million compared to $8.7 million in the prior year period [38] - Net loss for Q2 2022 was $19.4 million or $0.52 per share, compared to a net loss of $10 million or $0.35 per share in the prior year [40] Business Line Data and Key Metrics Changes - YUTIQ generated $7.4 million in revenue for Q2 2022, while DEXYCU contributed $3.9 million [32] - Customer demand for YUTIQ increased by approximately 40% from Q1 2022, with 900 units sold [32] - Customer demand for DEXYCU remained consistent with Q1 2022, with 14,700 units sold [32] Market Data and Key Metrics Changes - YUTIQ received approval for commercial use in China, marking a significant milestone for the company in expanding its global reach [14] - The company anticipates continued growth in customer demand for YUTIQ, particularly among retina specialists [33] Company Strategy and Development Direction - The company aims to become a leader in sustained ocular delivery, focusing on improving retinal treatment and bringing therapies to patients globally [17] - EYP-1901 is positioned as a maintenance therapy for wet AMD, with the goal of extending treatment intervals to up to six months [21] - The company is exploring additional indications for EYP-1901, including non-proliferative diabetic retinopathy (NPDR) [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of clinical trials and the potential of EYP-1901 to address significant unmet needs in ocular therapies [18][31] - The company is well-capitalized to fund operations into the second half of 2024, supporting ongoing clinical and commercial initiatives [40] Other Important Information - The company hosted its first Investor Day, showcasing its Durasert drug delivery platform and clinical results [13] - Two new Board appointments were made to strengthen the leadership team, including experts in ophthalmology and biopharmaceuticals [15][16] Q&A Session Summary Question: Will the company provide quarterly enrollment updates for the Phase 2 DAVIO 2 trial? - Management stated that they do not plan to provide such updates, as clinical trial enrollments can fluctuate significantly [44] Question: What are the powering assumptions for the DAVIO 2 trial? - Management indicated that specific statistics around DAVIO 2 have not been publicly announced yet, as the study is not powered to a high enough level for confidence [46] Question: What testing work led to the choice of 2 and 3 milligram doses for the diabetic retinopathy study? - The decision was based on the highest doses used in the DAVIO trial, as the maximally tolerated dose has not been established [52] Question: When will the company know about the CMS pass-through decision for DEXYCU? - The final rules are expected to be released in November, which will clarify the pass-through status [55] Question: Are there other molecules being explored for potential partnerships? - The company is looking at various molecules, including complement inhibitors, and is interested in partnering with companies that have proven mechanisms of action [67][70]

EyePoint Pharmaceuticals, Inc. (EYPT Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President & CEO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Eddie Hickman - Guggenheim Securities Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Good morning. My name is Jonathan. And I will be your conference operator today. At this time, I wo ...

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation November 2021 Forward looking statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not lim ...

PART I. FINANCIAL INFORMATION [Item 1. Unaudited Financial Statements](index=3&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) Unaudited financial statements for Q3 2021 show significant cash and asset growth from equity financing, a revenue shift to product sales, and a widened net loss due to increased operating expenses [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) | Balance Sheet Items (In thousands) | Sep 30, 2021 | Dec 31, 2020 | | :--- | :--- | :--- | | Cash and cash equivalents | $119,710 | $44,909 | | Total current assets | $141,775 | $63,118 | | Total assets | $168,251 | $91,717 | | Total current liabilities | $19,933 | $14,888 | | Long-term debt | $36,396 | $37,977 | | Total liabilities | $75,503 | $73,176 | | Total stockholders' equity | $92,748 | $18,541 | - The significant increase in cash and cash equivalents from **$44.9 million** to **$119.7 million** was primarily driven by proceeds from equity financing activities during the first nine months of 2021[7](index=7&type=chunk)[204](index=204&type=chunk) [Condensed Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) | Metric (In thousands) | Q3 2021 | Q3 2020 | 9 Months 2021 | 9 Months 2020 | | :--- | :--- | :--- | :--- | :--- | | Product sales, net | $8,587 | $5,758 | $24,127 | $14,151 | | License & collaboration revenue | $159 | $9,535 | $594 | $11,590 | | Total revenues | $9,059 | $15,695 | $25,395 | $27,306 | | R&D Expenses | $8,498 | $4,090 | $19,582 | $12,219 | | Total operating expenses | $24,372 | $17,652 | $62,621 | $51,859 | | Net loss | $(16,695) | $(3,801) | $(38,985) | $(29,925) | | Net loss per share | $(0.58) | $(0.30) | $(1.42) | $(2.44) | - The net loss for Q3 2021 widened significantly to **$16.7 million** from **$3.8 million** in Q3 2020, primarily due to a sharp decrease in high-margin license and collaboration revenue and a more than doubling of R&D expenses[11](index=11&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) | Cash Flow Activity (In thousands) | Nine months ended Sep 30, 2021 | Nine months ended Sep 30, 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(33,429) | $(20,330) | | Net cash used in investing activities | $(156) | $(170) | | Net cash provided by financing activities | $108,386 | $27,012 | | Net increase in cash | $74,801 | $6,512 | - Financing activities provided **$108.4 million** in cash, primarily from the issuance of stock, which more than offset the **$33.4 million** cash used in operations, resulting in a substantial increase in the company's cash position[17](index=17&type=chunk)[222](index=222&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The company's lead product candidate is EYP-1901, a potential twice-yearly treatment for wet AMD, which is currently in a Phase 1 clinical trial (DAVIO)[20](index=20&type=chunk)[22](index=22&type=chunk) - Commercial products include YUTIQ® for chronic non-infectious uveitis and DEXYCU® for postoperative inflammation following ocular surgery[20](index=20&type=chunk)[24](index=24&type=chunk) - The company believes its cash and cash equivalents of **$119.7 million** as of September 30, 2021, are sufficient to fund operations for at least the next twelve months[30](index=30&type=chunk) - In June 2021, the company's **$2.0 million** Paycheck Protection Program (PPP) loan was fully forgiven by the SBA, resulting in a gain on extinguishment of debt of approximately **$2.1 million**[99](index=99&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=28&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes increased product sales to recovering demand, notes a total revenue decrease from a one-time license payment, and highlights rising R&D expenses, with liquidity bolstered by a **$115.1 million** public offering [Business Overview and Recent Developments](index=30&type=section&id=Business%20Overview%20and%20Recent%20Developments) - Customer demand for YUTIQ and DEXYCU was negatively impacted by the COVID-19 pandemic but saw a modest return beginning in June 2020, which continued through 2021, although uncertainty remains due to new variants[161](index=161&type=chunk) - In February 2021, the company raised gross proceeds of approximately **$115.1 million** through an underwritten public offering of common stock[162](index=162&type=chunk) - The company completed enrollment in its Phase 1 DAVIO clinical trial for EYP-1901 for wet AMD in May 2021 and reported positive 3-month safety data in October 2021[171](index=171&type=chunk)[172](index=172&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q3 2021 vs Q3 2020 Performance (in thousands USD) | Metric | Q3 2021 (in thousands USD) | Q3 2020 (in thousands USD) | Change $ (in thousands USD) | Change % | | :--- | :--- | :--- | :--- | :--- | | Product sales, net | $8,587 | $5,758 | $2,829 | 49% | | License & collaboration | $159 | $9,535 | $(9,376) | (98)% | | Total revenues | $9,059 | $15,695 | $(6,636) | (42)% | | R&D Expenses | $8,498 | $4,090 | $4,408 | 108% | | Net loss | $(16,695) | $(3,801) | $(12,894) | (339)% | Nine Months 2021 vs 2020 Performance (in thousands USD) | Metric | 9M 2021 (in thousands USD) | 9M 2020 (in thousands USD) | Change $ (in thousands USD) | Change % | | :--- | :--- | :--- | :--- | :--- | | Product sales, net | $24,127 | $14,151 | $9,976 | 70% | | License & collaboration | $594 | $11,590 | $(10,996) | (95)% | | Total revenues | $25,395 | $27,306 | $(1,911) | (7)% | | R&D Expenses | $19,582 | $12,219 | $7,363 | 60% | | Net loss | $(38,985) | $(29,925) | $(9,060) | (30)% | - The **108%** increase in Q3 R&D expenses was primarily driven by **$1.6 million** in increased clinical costs for the EYP-1901 Phase 1 trial and planning for the YUTIQ 50 Phase 3 trial[182](index=182&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) - As of September 30, 2021, the company had cash and cash equivalents of **$119.7 million**, a significant increase from year-end 2020[204](index=204&type=chunk) - The company believes its current cash, combined with anticipated product sales, will fund its operating plan through December 31, 2022[211](index=211&type=chunk) - The company has a senior secured term loan with CRG, with an outstanding balance of approximately **$40.5 million** as of September 30, 2021. The loan includes financial covenants, such as maintaining liquidity above **$5 million** and meeting minimum annual product revenue targets, which were amended to **$25 million** for 2021[207](index=207&type=chunk)[209](index=209&type=chunk)[210](index=210&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) As a smaller reporting company, the company is exempt from providing quantitative and qualitative disclosures about market risk - As a smaller reporting company, EyePoint Pharmaceuticals is exempt from the requirement to provide quantitative and qualitative disclosures about market risk[225](index=225&type=chunk) [Item 4. Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2021, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of September 30, 2021, the company's principal executive officer and principal financial officer concluded that disclosure controls and procedures were effective[226](index=226&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended September 30, 2021, that materially affected, or are reasonably likely to materially affect, internal controls[227](index=227&type=chunk) PART II: OTHER INFORMATION [Item 1. Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The SEC's Division of Enforcement concluded its investigation into the company without recommending enforcement action, and other routine legal proceedings are not expected to have a material financial effect - On May 4, 2021, the SEC Division of Enforcement informed the company that it had concluded its investigation and did not intend to recommend an enforcement action[231](index=231&type=chunk)[148](index=148&type=chunk) [Item 1A. Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors from the 2020 Annual Report, except for a new disclosure concerning customer concentration for the DEXYCU product - A new risk factor was added regarding customer concentration, stating that a significant amount of DEXYCU is sold to a limited number of customers, and the loss of one or more could have a material adverse effect[233](index=233&type=chunk) [Other Items (Items 2, 3, 4, 5, 6)](index=40&type=section&id=Other%20Items%20%28Items%202%2C%203%2C%204%2C%205%2C%206%29) The company reported no unregistered equity sales, no defaults on senior securities, no mine safety disclosures, and no other material information, with Item 6 listing exhibits - The company reports 'None' for Unregistered Sales of Equity Securities, Defaults Upon Senior Securities, Mine Safety Disclosures, and Other Information[233](index=233&type=chunk)[234](index=234&type=chunk)[235](index=235&type=chunk)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants George Elston - Chief Financial Officer & Head, Corporate Development Nancy Lurker - President & Chief Executive Officer Jay Duker - Chief Strategic Scientific Officer Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen and Company Yatin Suneja - Guggenheim Partners Yi Chen - H.C. Wainwright Yale Jen - Laidlaw An ...

Financial Data and Key Metrics Changes - For Q1 2021, total net revenue was $7.3 million, a decrease from $7.5 million in Q1 2020. Net product revenue was $6.8 million, up 45% from $4.7 million in Q1 2020 [20][21] - The net loss for Q1 2021 was $12.3 million, or $0.50 per share, compared to a net loss of $13.2 million, or $1.14 per share, in the prior year [21] - Cash and cash equivalents at March 31, 2021, totaled $138.6 million, significantly up from $44.9 million at December 31, 2020 [21] Business Line Data and Key Metrics Changes - Net product revenue for YUTIQ was $3.8 million and for DEXYCU was $3 million in Q1 2021, with customer demand for DEXYCU at approximately 7,000 units and for YUTIQ at 400 units [16] - The introduction of a new siliconized needle for YUTIQ is expected to enhance patient and physician experience [8][17] Market Data and Key Metrics Changes - The company reported a strong first quarter despite the ongoing challenges of the COVID-19 pandemic, with a 45% increase in net product revenues compared to the previous year [8][15] - The Asia partner, Ocumension Therapeutics, received approval for review of a new drug application for YUTIQ in China, indicating potential for future revenue streams [9] Company Strategy and Development Direction - The company aims to expand its product pipeline and drive growth for its commercial products, targeting profitability for DEXYCU and YUTIQ by year-end [9][18] - Plans to initiate studies for EYP-1901 in diabetic retinopathy and retinal vein occlusion are underway, with hopes to start these studies in late 2021 or early 2022 [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of the Wet AMD market due to the aging population and the need for innovative treatment options [24] - The company remains focused on maintaining a strong balance sheet and disciplined spending to support its growth initiatives [9][21] Other Important Information - The company successfully completed a $115.1 million follow-on offering to strengthen its balance sheet [7] - The revenue covenant with CRG was reduced to $25 million at no cost, reflecting improved financial conditions [8][20] Q&A Session Summary Question: How will the Wet AMD space evolve over the next 5 to 10 years? - Management believes the demand will continue to grow due to the aging population and the prevalence of the disease, with a place for innovative drugs like EYP-1901 [24][25] Question: What are the opportunities in other retinal indications? - The company is evaluating studies in diabetic retinopathy and retinal vein occlusion, which are large patient populations [28] Question: Can you provide spending guidance for the year? - Q1 spending is a good run rate, with expectations for continued investment in clinical trials [30][31] Question: What is the status of the SEC investigation? - The SEC concluded its investigation with no intent to recommend enforcement action, which the company views positively [36][37] Question: What trends are seen in retinal specialists and ASCs? - Most cataract surgery centers are returning to normal, though some academic centers still face restrictions [38] Question: What is the expected efficacy of EYP-1901 compared to existing treatments? - Management believes that extended delivery could lead to better patient outcomes, although long-term studies are needed to confirm this [56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...